{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:20:14Z","timestamp":1791638414235,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,9,15]],"date-time":"2016-09-15T00:00:00Z","timestamp":1473897600000},"content-version":"vor","delay-in-days":380,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jacc.2015.07.018","type":"journal-article","created":{"date-parts":[[2015,9,7]],"date-time":"2015-09-07T18:51:44Z","timestamp":1441651904000},"page":"1273-1285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Long-Term Use of Cardiovascular Drugs"],"prefix":"10.1016","volume":"66","author":[{"given":"Xavier","family":"Rossello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond G.","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2015.07.018_bib1","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib2","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib3","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/S0735-1097(98)00609-3","article-title":"Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials","volume":"33","author":"Domanski","year":"1999","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib4","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2005.11.073","article-title":"Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials","volume":"47","author":"Al-Mallah","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib5","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1136\/bmj.318.7200.1730","article-title":"\u03b2 Blockade after myocardial infarction: systematic review and meta regression analysis","volume":"318","author":"Freemantle","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2015.07.018_bib6","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0140-6736(15)60110-6","article-title":"Effects of long-term use of cardiovascular drugs","volume":"385","author":"Julian","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib7","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1016\/j.jacc.2012.11.019","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the\u00a0American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"61","author":"O\u2019Gara","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib8","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1016\/j.jacc.2012.07.013","volume":"60","author":"Fihn","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib9","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC Guideline for the Management of Patients With Non\u2013ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2015.07.018_bib11","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib12","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.7326\/M14-1430","article-title":"Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States","volume":"162","author":"Odden","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib15","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.jacc.2011.10.824","volume":"58","author":"Smith","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib16","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/01.CIR.97.22.2202","article-title":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials","volume":"97","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.07.018_bib17","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa042739","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"351","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib18","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1093\/eurheartj\/ehu078","article-title":"Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure","volume":"35","author":"Sorbets","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.07.018_bib19","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1016\/j.jacc.2014.08.021","article-title":"A\u00a0polypill strategy to improve adherence: results from the FOCUS project","volume":"64","author":"Castellano","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib20","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/eurheartj\/eht407","article-title":"Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges","volume":"35","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.07.018_bib21","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib22","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.07.018_bib23","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/bmj.1.5905.436","article-title":"A\u00a0randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction","volume":"1","author":"Elwood","year":"1974","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2015.07.018_bib24","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0021-9681(76)90020-5","article-title":"Aspirin in coronary heart disease","volume":"29","year":"1976","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.jacc.2015.07.018_bib25","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/S0140-6736(79)92808-3","article-title":"Aspirin and secondary mortality after myocardial infarction","volume":"2","author":"Elwood","year":"1979","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1161\/01.CIR.62.3.449","article-title":"Persantine and aspirin in coronary heart disease","volume":"62","year":"1980","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2015.07.018_bib27","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/jama.1980.03300330019023","article-title":"A\u00a0randomized, controlled trial of aspirin in persons recovered from myocardial infarction","volume":"243","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib28","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib29","first-page":"810","article-title":"Results of the low-dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge?","volume":"1","year":"2000","journal-title":"Ital Heart J"},{"key":"10.1016\/j.jacc.2015.07.018_bib30","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib31","first-page":"1772","article-title":"Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study","volume":"44","author":"Koren","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib32","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib33","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a\u00a0delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"De Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib34","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib35","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib36","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib37","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/bmj.3.5986.735","article-title":"Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study","volume":"3","year":"1975","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2015.07.018_bib38","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0140-6736(82)92225-5","article-title":"Controlled trial of sotalol for one year after myocardial infarction","volume":"319","author":"Julian","year":"1982","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/oxfordjournals.eurheartj.a061636","article-title":"European Infarction Study (E.I.S.): a secondary prevention study with slow release oxprenolol after myocardial infarction: morbidity and mortality","volume":"5","year":"1984","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.07.018_bib40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/oxfordjournals.eurheartj.a061844","article-title":"Very early intervention with metoprolol in suspected acute myocardial infarction","volume":"6","author":"Salathia","year":"1985","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.07.018_bib41","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1093\/oxfordjournals.eurheartj.a062170","article-title":"The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction","volume":"8","year":"1987","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2015.07.018_bib42","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement Trial","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib44","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1056\/NEJM199512213332503","article-title":"A\u00a0clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction","volume":"333","author":"K\u00f8ber","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib45","first-page":"821","article-title":"Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure","volume":"342","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib46","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction","volume":"345","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib47","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0002-9149(01)01461-8","article-title":"The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function","volume":"87","author":"Pitt","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib48","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1001\/jama.292.18.2217","article-title":"Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial","volume":"292","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib49","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14286-9","article-title":"Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)","volume":"362","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib50","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/j.jacc.2014.08.037","article-title":"Short- and long-term cause of death in patients treated with primary PCI for STEMI","volume":"64","author":"Pedersen","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib51","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jacc.2003.09.071","article-title":"Does beta-blocker therapy improve clinical outcomes of\u00a0acute myocardial infarction after successful primary angioplasty?","volume":"43","author":"Kernis","year":"2004","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib52","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","article-title":"\u03b2-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease","volume":"308","author":"Bangalore","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib53","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","article-title":"Myocardial infarction redefined\u2013a consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction","volume":"36","author":"Antman","year":"2000","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib54","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1016\/j.jacc.2007.09.011","article-title":"Universal definition of myocardial infarction","volume":"50","author":"Thygesen","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib55","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib56","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/ageing\/afr115","article-title":"Improving\u00a0recruitment of older people to research through good practice","volume":"40","author":"McMurdo","year":"2011","journal-title":"Age Ageing"},{"key":"10.1016\/j.jacc.2015.07.018_bib57","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib58","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib59","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib60","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/jama.287.3.337","article-title":"Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey","volume":"287","author":"Kaufman","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib62","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/gerona\/glv013","article-title":"Polypharmacy among adults aged 65 years and older in the United States: 1988-2010","volume":"70","author":"Charlesworth","year":"2015","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jacc.2015.07.018_bib63","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1472-8206.2009.00757.x","article-title":"The challenge of polypharmacy in cardiovascular medicine","volume":"24","author":"Volpe","year":"2010","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.jacc.2015.07.018_bib64","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1001\/jama.2008.892","article-title":"Use\u00a0of prescription and over-the-counter medications and dietary supplements among older adults in the United States","volume":"300","author":"Qato","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib65","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1001\/jama.289.9.1107","article-title":"Incidence and preventability of adverse drug events among older persons in the ambulatory setting","volume":"289","author":"Gurwitz","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib66","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00228-013-1639-9","article-title":"Prevalence of polypharmacy in a Scottish primary care population","volume":"70","author":"Payne","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2015.07.018_bib67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/nrcardio.2010.162","article-title":"Cardiovascular drug therapy in the elderly: benefits and challenges","volume":"8","author":"Fleg","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib68","doi-asserted-by":"crossref","first-page":"266","DOI":"10.7326\/M14-1281","article-title":"An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort","volume":"162","author":"DeFilippis","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib69","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2015.02.025","article-title":"One size may not fit all: using age- and sex-specific risk thresholds to guide statin therapy","volume":"65","author":"Navar-Boggan","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib70","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7861\/clinmedicine.15-1-47","article-title":"Drug therapies in older adults (part 1)","volume":"15","author":"Mukhtar","year":"2015","journal-title":"Clin Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib71","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2015.07.018_bib72","doi-asserted-by":"crossref","first-page":"g6196","DOI":"10.1136\/bmj.g6196","article-title":"Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study","volume":"349","author":"Fralick","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2015.07.018_bib73","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00002512-199812060-00006","article-title":"Important drug-drug interactions in the elderly","volume":"12","author":"Seymour","year":"1998","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jacc.2015.07.018_bib74","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2015.07.018_bib75","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1001\/jama.286.6.708","article-title":"Representation of elderly persons and women in published randomized trials of acute coronary syndromes","volume":"286","author":"Lee","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2015.07.018_bib76","doi-asserted-by":"crossref","first-page":"g7013","DOI":"10.1136\/bmj.g7013","article-title":"Discontinuing drug treatments","volume":"349","author":"Gnjidic","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2015.07.018_bib77","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2014.08.008","article-title":"Do current clinical trials meet society\u2019s needs? A critical review of the evidence","volume":"64","author":"Pocock","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib78","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jacc.2015.01.039","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials","volume":"65","author":"Giustino","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib79","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2015.07.018_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2014.09.039","article-title":"Impact of postdischarge statin withdrawal on long-term outcomes in patients with acute myocardial infarction","volume":"115","author":"Kim","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2015.07.018_bib81","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.pharmthera.2009.03.019","article-title":"Possibility of a rebound phenomenon following antiplatelet therapy withdrawal: a look at the clinical and pharmacological evidence","volume":"123","author":"Lordkipanidz\u00e9","year":"2009","journal-title":"Pharmacol Ther"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109715044630?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109715044630?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,30]],"date-time":"2019-08-30T07:33:21Z","timestamp":1567150401000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109715044630"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":81,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0735109715044630"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2015.07.018","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Use of Cardiovascular Drugs","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2015.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}